Discover Dermatology LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$261,147	61
2024	Research	$18,552	2

Breakdown

Who paid Research payments · program years 2024–2025

Sun Pharmaceutical Industries Inc. $109,991 22 payments
Hoffmann-La Roche Limited $54,355 24 payments
Novartis Pharmaceuticals Corporation $48,955 3 payments
Ucb SA $27,877 2 payments
Pfizer Inc. $24,220 7 payments
Genentech, Inc. $14,300 5 payments

Studies the money was for Research payments · program years 2024–2025

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis $109,991 22 payments
Velarite $68,655 29 payments
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $48,955 3 payments
Presto Characterization and Clinical Outcomes of Alopecia Aerata Aa Patients Treated With Ritlecitinib in A Realworld RW Cohort A Multinational Prospective Observational Study $24,220 7 payments
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant, Investigator, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $15,325 1 payment
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $12,552 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.